Teva’s $420mn investor settlement to be mostly covered by insurers

Teva has agreed a $420mn settlement of shareholder litigation over an alleged anti-competitive scheme to fix generic drug pricing, with a spokesperson for the pharmaceutical company telling Reuters the “vast majority” will be covered by insurers.


Want to read this article?


For details on how to subscribe or for all commercial opportunities, including advertising, please contact:

Spencer Halladey

Commercial director

+44 (0) 7540 000929

    Andy Stone

    Sales manager

    +44 (0) 7834 843176